Alba Garcia Lopez

Farmacéutica especialista en Onco-Hematología. BCOP. Salud y Revolución!

[Erman Akkus @Erman_Akkus]

🧭Treatment of metastatic CRC
#ASCO24 @ASCO

[Alba Garcia Lopez @AlbaGarLop22]

Practice changing! Osimertinib tras QT-RT en pacientes con NSCLC irresecable con mutación en EGFR en estadio III: LAURA trial #ASCO24 #ASCO24SEFH

[Vinay Prasad MD MPH @VPrasadMDMPH]

Great figure by @Timothee_MD
We already had a better drug in 2017. Its disappointing to see docs run a trial with a control arm they would not let their mother get. We explain here
#asco24 #asco2024

https://t.co/I1SkFKB9A9

[NEJM @NEJM]

Presented at #ASCO24:

ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. https://t.co/PMPF00jUjF

[Alba Garcia Lopez @AlbaGarLop22]

Arrancamos! #asco24sefh @LAILAABDELKADE1 @Helenro77